WO2017203367A3 - Methods for treatment of non-alcoholic hepatic steatosis and hepatic steatohepatitis using ileal brake hormone releasing substance - Google Patents

Methods for treatment of non-alcoholic hepatic steatosis and hepatic steatohepatitis using ileal brake hormone releasing substance Download PDF

Info

Publication number
WO2017203367A3
WO2017203367A3 PCT/IB2017/000780 IB2017000780W WO2017203367A3 WO 2017203367 A3 WO2017203367 A3 WO 2017203367A3 IB 2017000780 W IB2017000780 W IB 2017000780W WO 2017203367 A3 WO2017203367 A3 WO 2017203367A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
steatohepatitis
nash
hepatitis
conditions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2017/000780
Other languages
French (fr)
Other versions
WO2017203367A2 (en
Inventor
Jerome Schentag
Joseph M. Fayad
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Volant Holdings GmbH
Original Assignee
Volant Holdings GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Volant Holdings GmbH filed Critical Volant Holdings GmbH
Publication of WO2017203367A2 publication Critical patent/WO2017203367A2/en
Publication of WO2017203367A3 publication Critical patent/WO2017203367A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention is directed to a System characterization of NASH that combines Modeling and Biomarkers, enabling pharmaceutical compositions and methods of treatment that relate to the inhibition, resolution and/or prevention of Non Alcoholic Fatty Liver Disease (NAFLD) and Hon Alcoholic Steatohepatitis (NASH). Said conditions are Liver related complications among the array of manifestations of.metabolic syndromes, including Type 2 diabetes, hyperlipidemia, weight gain, abdominal obesity, insulin resistance, hypertension, atherosclerosis, fatty liver diseases and certain chronic inflammatory states that lead to these manifestations, among others. In additional aspects, the present invention relates to compositions and methods which may be used to treat inhibit or reduce the likelihood of NASH and NAFLD complications in patients with hepatitis viral infections, including Hepatitis B and Hepatitis C viral infections, as well as the secondary disease states and/or conditions which are often associated with such viral infections, including hepatic steatosis (steatohepatitis), cirrhosis, fatty liver and hepatocellular cancer, metabolic syndrome complications including cardiovascular diseases, neurodegenerative diseases and premature ageing, among other disease states or conditions.
PCT/IB2017/000780 2016-05-22 2017-05-22 Diagnostics and methods for treatment of non-alcoholic hepatic steatosis and hepatic steatohepatitis, and prevention of complications thereof Ceased WO2017203367A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662339904P 2016-05-22 2016-05-22
US62/339,904 2016-05-22

Publications (2)

Publication Number Publication Date
WO2017203367A2 WO2017203367A2 (en) 2017-11-30
WO2017203367A3 true WO2017203367A3 (en) 2018-03-01

Family

ID=59626635

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2017/000780 Ceased WO2017203367A2 (en) 2016-05-22 2017-05-22 Diagnostics and methods for treatment of non-alcoholic hepatic steatosis and hepatic steatohepatitis, and prevention of complications thereof

Country Status (1)

Country Link
WO (1) WO2017203367A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108932976A (en) * 2018-06-11 2018-12-04 西安医学院 A kind of non-alcohol fatty liver Noninvasive diagnosis program
CN109359762B (en) * 2018-08-23 2021-07-20 创新先进技术有限公司 Risk prediction model generation method, risk prediction method, device and server
CN109374890A (en) * 2018-11-07 2019-02-22 国家纳米科学中心 Breast cancer detection system and method based on thermophoretic extracellular vesicle detection
PT3911647T (en) * 2019-01-15 2024-03-04 Gilead Sciences Inc Fxr (nr1h4) modulating compounds
CN113599523B (en) * 2021-08-30 2023-02-03 秦绪军 Application of GPx8 as molecular target in preparation of medicine for preventing and/or treating fatty liver
CN115927592B (en) * 2022-11-07 2024-06-28 中南大学湘雅医院 Application of Csde1 gene as a target in the preparation of drugs for treating non-alcoholic fatty liver disease
CN117904290B (en) * 2023-12-13 2024-07-23 暨南大学 Application of IL-21R in the preparation of diagnostic and prognostic prediction products and therapeutic drugs for non-alcoholic steatohepatitis-related liver cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012118712A2 (en) * 2011-03-02 2012-09-07 Jerome Schentag Compositions, methods of treatment and diagnostics for treatment of hepatic steatosis alone or in combination with a hepatitis c virus infection
US20140294951A1 (en) * 2011-10-26 2014-10-02 Joseph M. Fayad Oral formulations mimetic of Roux-en-Y gastric bypass actions on the ileal brake; Compositions, methods of treatment, diagnostics and systems for treatment of metabolic syndrome manifestations including insulin resistance, fatty liver disease, hyperlipidemia, and T2D
WO2016011335A1 (en) * 2014-07-17 2016-01-21 Jerome Schentag Activation of the endogenous ileal brake hormone pathway for organ regeneration and related compositions, methods of treatment, diagnostics, and regulatory systems

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012118712A2 (en) * 2011-03-02 2012-09-07 Jerome Schentag Compositions, methods of treatment and diagnostics for treatment of hepatic steatosis alone or in combination with a hepatitis c virus infection
US20140294951A1 (en) * 2011-10-26 2014-10-02 Joseph M. Fayad Oral formulations mimetic of Roux-en-Y gastric bypass actions on the ileal brake; Compositions, methods of treatment, diagnostics and systems for treatment of metabolic syndrome manifestations including insulin resistance, fatty liver disease, hyperlipidemia, and T2D
WO2016011335A1 (en) * 2014-07-17 2016-01-21 Jerome Schentag Activation of the endogenous ileal brake hormone pathway for organ regeneration and related compositions, methods of treatment, diagnostics, and regulatory systems

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
P. J. MALJAARS ET AL: "An ileal brake-through?", THE AMERICAN JOURNAL OF CLINICAL NUTRITION, vol. 92, no. 3, 4 August 2010 (2010-08-04), US, pages 467 - 468, XP055418329, ISSN: 0002-9165, DOI: 10.3945/ajcn.2010.30180 *
THER ADV: "Therapeutic Advances in Gastroenterology Review", 1 January 2012 (2012-01-01), pages 199 - 207, XP055418336, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3342568/pdf/10.1177_1756283X11430859.pdf> *

Also Published As

Publication number Publication date
WO2017203367A2 (en) 2017-11-30

Similar Documents

Publication Publication Date Title
WO2017203367A3 (en) Methods for treatment of non-alcoholic hepatic steatosis and hepatic steatohepatitis using ileal brake hormone releasing substance
WO2012118712A3 (en) Compositions, methods of treatment and diagnostics for treatment of hepatic steatosis alone or in combination with a hepatitis c virus infection
Xu et al. Targeting inflammation for the treatment of alcoholic liver disease
EA201790124A1 (en) SALT BERBERIN, SALT URSODEZOXYCHOLEIC ACID AND THEIR COMBINATION, METHODS OF OBTAINING AND APPLICATION
EP4234038A3 (en) Compositions comprising heptadecanoic acid for the treatment of inflammation and related conditions
EP4674862A3 (en) Peptides for treatment and prevention of nonalcoholic fatty liver disease and fibrosis
JP2014094951A5 (en)
JO3686B1 (en) Glucagon and glp-1 co-agonist compounds
Pollheimer et al. Chronic cholestatic liver diseases: clues from histopathology for pathogenesis
JP2018507914A5 (en)
BR112018074452A2 (en) liver fibrosis treatment method
EA201592020A1 (en) NEW COMPOSITION FOR NONALCOHOLIC FATIAL LIVER DISEASE (NAFLD)
WO2016127019A3 (en) Pharmaceutical compositions for combination therapy
WO2014106846A3 (en) Methods and compositions for treating nafld, hepatic steatosis, and sequelae thereof
JP2012525376A5 (en)
JP2017515854A5 (en)
PH12019550226A1 (en) Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
JP2018505158A5 (en)
EP3892289A4 (en) Pharmaceutical composition, comprising inhibitory peptide against fas signaling, for prevention or treatment of obesity, fatty liver, or steatohepatitis
JP2021535175A5 (en)
WO2016046680A3 (en) Compositions and methods for the treatment of liver metabolic diseases
EP3718552A4 (en) Combination drug suitable for treatment and prevention of non-alcoholic fatty liver disease (naflad) and/or non-alcoholic steatohepatitis (nash), and/or hepatic steatosis
MX2019002579A (en) Compositions and methods of use of gamma-ketoaldehyde scavengers for treating, preventing or improving nonalcoholic fatty liver disease (nafld), nash, ald or conditions related to the liver.
EA201990883A1 (en) BERBERIN SALTS, UROSODESOXYCHOLIC ACID SALTS AND THEIR COMBINATIONS, METHODS FOR PRODUCING AND USE
MX2022007929A (en) Stapled triazole co-agonists of the glucagon and glp-1 receptors.

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17752164

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 17752164

Country of ref document: EP

Kind code of ref document: A2